Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12436661 | 0.90 | HSD11B1 (0.41) | HSD11B1ASGR1BTKCHRM2CHRM1 | |
| SCHEMBL26401377 | 0.90 | HSD11B1 (0.41) | HSD11B1ASGR1BTKCHRM2CHRM1 | |
| SCHEMBL181714 | 0.87 | BTK (0.44) | HSD11B1ASGR1BTKCHRM2CHRM1 | |
| SCHEMBL1663087 | 0.87 | BTK (0.44) | HSD11B1ASGR1BTKCHRM2CHRM1 | |
| SCHEMBL16513085 | 0.87 | BTK (0.44) | HSD11B1ASGR1BTKCHRM2CHRM1 | |
| SCHEMBL2847124 | 0.87 | BTK (0.44) | HSD11B1ASGR1BTKCHRM2CHRM1 | |
| SCHEMBL16486601 | 0.86 | HSD11B1 (0.41) | HSD11B1ASGR1BTKCHRM2CHRM1 | |
| SCHEMBL16513090 | 0.86 | HSD11B1 (0.41) | HSD11B1ASGR1BTKCHRM2CHRM1 | |
| SCHEMBL29919319 | 0.84 | HSD11B1 (0.41) | HSD11B1ASGR1BTKCHRM2CHRM1 | |
| SCHEMBL25982410 | 0.84 | HSD11B1 (0.41) | HSD11B1ASGR1BTKCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | HSD11B1 29/4885ASGR1 1187/4885BTK 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.